ATC Group: B01AF Direct factor Xa inhibitors

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B01AF in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B01 Antithrombotic agents
3 B01A Antithrombotic agents
4 B01AF Direct factor Xa inhibitors

Group B01AF contents

Code Title
B01AF01
B01AF02
B01AF03
B01AF04
B01AF51

Active ingredients in B01AF

Active Ingredient Description
Apixaban

Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa, and prothrombinase activity. By inhibiting factor Xa, apixaban prevents thrombin generation and thrombus development.

Betrixaban
Edoxaban

Edoxaban is a highly selective, direct and reversible inhibitor of factor Xa, the serine protease located in the final common pathway of the coagulation cascade. Edoxaban inhibits free factor Xa, and prothrombinase activity. Inhibition of factor Xa in the coagulation cascade reduces thrombin generation, prolongs clotting time and reduces the risk of thrombus formation.

Rivaroxaban

Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

Related product monographs

Title Information Source Document Type  
ELIQUIS Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
LIXIANA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ROTEAS Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
XARELTO 10mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
XARELTO 15mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
XARELTO 15mg/20mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
XARELTO 2.5mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC